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Abstract: Children with severe impairment of the central nervous system (CNS) experience
gastrointestinal (GI) symptoms at a high rate and severity, including retching, vomiting, GI tract
pain, and feeding intolerance. Commonly recognized sources of symptoms include constipation
and gastroesophageal reflux disease. There is growing awareness of sources due to the impaired
nervous system, including visceral hyperalgesia due to sensitization of sensory neurons in the enteric
nervous system and central neuropathic pain due to alterations in the thalamus. Challenging the
management of these symptoms is the lack of tests to confirm alterations in the nervous system
as a cause of symptom generation, requiring empirical trials directed at such sources. It is also
common to have multiple reasons for the observed symptoms, further challenging management.
Recurrent emesis and GI tract pain can often be improved, though in some not completely eliminated.
In some, this can progress to intractable feeding intolerance. This comprehensive review provides
an evidence-based approach to care, a framework for recurrent symptoms, and language strategies
when symptoms remain intractable to available interventions. This summary is intended to balance
optimal management with a sensitive palliative care approach to persistent GI symptoms in children
with severe impairment of the CNS.
Keywords: pediatric; neurological impairment; feeding intolerance; retching; visceral hyperalgesia; central
neuropathic pain; autonomic dysfunction; disability; pediatric palliative care; symptom management
1. Introduction
Retching, vomiting, and gastrointestinal (GI) pain are frequent and significant problems
experienced by children with severe impairment of the central nervous system (CNS), often referred to
as children with severe neurological impairment (SNI) [1–9]. The GI tract is one of the most frequent
sources of pain in children with SNI despite treatment of common sources such as gastroesophageal
reflux disease (GERD) and constipation [2–6,10]. Pain attributed to the GI tract is noted to have a high
pain intensity of 7.5 (from a 0–10 scale), second only to pain of unknown cause, with significantly higher
rates of pain in children already receiving treatment for GERD or impaired GI tract motility [2,5,10].
Many continue to have recurrent symptoms despite evaluation and treatment directed at such
problems, and such children may experience repeated testing in search of a cause.
These problems can result in feeding intolerance that for some can become a recurrent and
persistent problem despite management of commonly recognized sources. This was identified as
one of the most common problems in children with progressive genetic, metabolic, or neurologic
conditions with no cure, with pain, sleep, and feeding difficulties identified by parents as the three
most common problems, with symptoms often not well controlled [11].
Children 2018, 5, 1; doi:10.3390/children5010001 www.mdpi.com/journal/children
Children 2018, 5, 1 2 of 11
This article will focus on GI symptoms that are recurrent and persistent in children with SNI.
The goal of this article is to provide evidence-based suggestions to guide empirical treatment trials.
This includes a review of how the altered CNS can contribute to such symptoms and interventions to
modify how these symptoms are generated.
2. A Framework
Children with SNI and recurrent retching, emesis, and feeding intolerance often have multiple
sources that contribute to these symptoms. As a starting framework, some are common management
issues such as constipation and minimizing excessive calories, some are due to the altered CNS, and
some are acute problems that can worsen the chronic symptoms. Further considerations include:
• Problems with tests that are “fixable”: urinary tract infection (UTI), acute pancreatitis, cholecystitis,
nephrolithiasis, volvulus, helicobacter pylori.
• Problems with tests that can be modified and empirically managed: GERD, dysmotility.
• Problems without tests due to the altered nervous system that can be modified, require empirical
trials, and can remain intractable: autonomic dysfunction, altered enteric nervous system, visceral
hyperalgesia, central neuropathic pain, altered vomiting center in the medulla.
• Problems due to a wide range of needs in the same group of children: calorie and fluid estimates.
3. Testable Causes
Causes of acute emesis and abdominal pain typically have a diagnostic test to then guide treatment.
Causes to consider include acute gastroenteritis, urinary tract infection, acute pancreatitis, nephrolithiasis,
cholecystitis, volvulus, superior mesenteric artery syndrome, or adhesions. When symptoms persist,
causes due to the altered nervous system (Table 1) are important to consider in a child with negative
tests and insufficient benefit from treatment for such problems as GERD.
4. Causes Due to the Altered Nervous System
4.1. Visceral Hyperalgesia and Central Neuropathic Pain
Visceral hyperalgesia is an altered threshold to pain generation in response to a stimulus in the GI
tract [12]. As a result, a normal stimulus, such as distention and pressure within the GI tract, can result
in pain. Alternatively, tissue inflammation or injury, such as from GERD or surgery to the GI tract,
may result in sensitization of visceral afferent pathways, with resulting visceral hyperalgesia.
Central neuropathic pain can develop when injury or disease of the CNS involves the thalamus
or spinothalamic tract [13–15]. Symptoms due to this cause of pain include visceral pain associated
with distention of the GI tract and bladder, described by one adult as feeling “like my bowels will
explode” [16].
Both are reviewed together given the inability to know when GI tract pain is due to sensitization
of sensory neurons in the enteric nervous system or a result of altered descending inhibitory control.
Both can be suggested by (1) pain, retching and vomiting associated with gastrostomy tube (G-tube)
feedings as a result of decreased gastric volume threshold to symptom generation; (2) pain associated
with intestinal gas and jejunostomy tube (J-tube) feedings, suggesting pain with intestinal distention;
(3) pain associated with flatus and bowel movements suggesting pain associated with colonic
distention; and (4) persistent symptoms despite treatment of an identified problem such as GERD.
The inability to tolerate a reasonable feeding rate may indirectly indicate a decreased threshold to
symptom generation from GI tract distention.
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Table 1. Chronic sources of retching, emesis, and visceral pain.
Cause Management Options Comments
Constipation
Polyethylene glycol
Lactulose
Milk of Magnesia
Senna
Colonic distention from constipation can trigger pain symptoms due to visceral hyperalgesia
and central neuropathic pain
GERD,
motility disorders
H-2 blockers and PPIs
Protective barrier: sucralfate
Promotility drugs: erythromycin,
metoclopramide
Jejunostomy feeding tube
Motility disorders can be a result of impaired input from the CNS to the enteric nervous system
Suggested by bloating, distension, retching, vomiting, discomfort
Other problems can contribute, including constipation and pain
Vomiting reflex
Medications that block the 5HT-2, 5HT-3,
H-1, Ach, and D-2 receptors
Cyproheptadine (5HT-2, H-1, Ach)
Ondansetron (5HT-3)
Suggested by retching, forceful vomiting, and associated symptoms of sweating, pale skin, and
appearing distressed
Visceral hyperalgesia,
central neuropathic pain
Gabapentin
Pregabalin
Tricyclic antidepressants
Suggested by pain, retching, and emesis associated with feedings, intestinal gas, flatus, and
bowel movements
Autonomic dysfunction
Gabapentin
Pregabalin
Clonidine
Suggested by pain and emesis associated with tachycardia, hyperthermia, diaphoresis, and
skin flushing
Pseudo-obstruction
Conservative management
Erythromycin
Neostigmine or pyridostigmine
Suggested by recurrent episodes of abdominal distension, pain, emesis, and severe
constipation, in the absence of mechanical obstruction
Ach: acetylcholine; CNS: central nervous system; D: dopamine; H: histamine; 5HT: serotonin; GERD: gastroesophageal reflux disease; PPI: proton pump inhibitor.
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Two considerations to management are: interventions that lessen GI tract distention and
medications that lessen symptom generation. The former includes alterations in feeding volume
rate, a review of calorie estimates, and G-tube venting, as examples. The later can include medication
trials directed at visceral hyperalgesia and central neuropathic pain (Table 1).
Medication options for both include gabapentin and tricyclic antidepressants (TCAs) [13–19].
In addition, use of gabapentin for persistent pain in children with SNI resulted in a significant reduction
of associated GI symptoms, including decreased emesis and retching, improved feeding tolerance,
weight gain, and change from J-tube to G-tube feedings [17,20,21]. Clonidine also has suggested benefit
in reducing pain perception during gastric and colonic distension [22].
4.2. Autonomic Dysfunction
Autonomic dysfunction, also called dysautonomia, paroxysmal sympathetic hyperactivity,
autonomic storming, or sympathetic storming, can be due to alterations in the hypothalamus in
children with SNI. Symptoms include tachycardia, hyperthermia, flushing of skin, abdominal pain,
vomiting, bowel dysmotility, constipation, urinary retention, excessive sweating, increased salivation,
posturing, and agitation [23–25].
Literature is limited to case reports, predominantly in patients with hypoxic and traumatic
brain injury, with mixed results for interventions reported including benzodiazepines, bromocriptine,
clonidine, oral and intrathecal baclofen (ITB), beta antagonists, and morphine sulfate [26–29].
More recently reported interventions include gabapentin and pregabalin [25,30]. In addition to
scheduled gabapentinoid or clonidine, children with intermittent “autonomic storms” may benefit
from as needed clonidine, benzodiazepine, or morphine sulfate during these episodes.
4.3. Emetic Reflex and Vomiting Center
The emetic reflex is the mechanism by which the CNS protects the body from potentially toxic
substances. This complex reflex involves input to the vomiting center (VC), the final pathway.
Receptors in the VC include histamine (H-1), acetylcholine (Ach), and serotonin (5HT-2) [31].
Alterations in the GI tract can stimulate the VC, predominantly mediated through the vagus and
sympathetic nerves. The receptors involved include various serotonin (5HT) receptors in the GI tract
including 5HT-4 prokinetic receptors and dopamine (D-2) receptors in the gastric wall. Substance P
has also been identified in the GI tract, a neurotransmitter that induces vomiting through stimulation
of the neurokinin (NK-1) receptors located in the chemoreceptor trigger zone.
Stimulation of these receptors can involve either distention or inflammation in the GI tract.
Distention is detected by mechanoreceptors and inflammation by chemoreceptors. The goal is to treat
sources when possible and block triggered receptors when the source cannot be fully eliminated. As an
example, altered motility can result in recurrent distention of the intestines and colon. Treatment to
modify motility is intended to minimize development of symptoms, with medications that target
involved receptors then lessening symptom generation.
Medications that block these receptors include cyproheptadine and ondansetron (Table 2).
Some medications, such as cyproheptadine, block more than one receptor involved with triggering the
emetic reflex. Cyproheptadine has been identified to improve feeding tolerance, decrease emesis, and
decrease retching including after fundoplication [32,33].
Children 2018, 5, 1 5 of 11
Table 2. Interventions for chronic retching, vomiting, and visceral pain.
Intervention Comments
Treat constipation Minimizes colonic distension and further slowing of motility
Assess for over-feeding
Children at highest risk: intermittent hypothermia, minimal movement of extremities,
decreased movement following symptom reduction, gradual health decline
Initiate 30% reduction and monitor for 2–4 weeks
Review bolus volume
and feed rate Suggested guidelines: bolus < 15 mL/kg per bolus, continuous rate < 8 mL/kg/h [34]
Review osmolarity
of feeds
Minimize use of elemental formulas or dilute, use additives to add calories without
adding osmotic load (microlipid)
Gastric acid reduction
and protective barrier:
H-2 blockers, PPIs,
sucralfate, antacids
Consider 8–12 weeks treatment course: chronic use of PPIs associated with
Clostridium difficile, small bowel bacterial overgrowth, pneumonia, bone fracture,
and hypomagnesemia
Anticipate gastric acid rebound when a PPI is stopped; consider managing with
short-term use of antacids or H-2 blocker
Gabapentin, pregabalin Treatment of visceral hyperalgesia and dysautonomia
Tricyclic antidepressant Treatment of visceral hyperalgesia and central neuropathic pain
Clonidine Treatment of symptoms due to dysautonomia
Cyproheptadine Blocks receptors that trigger the VC (5HT-2, H-1, and Ach)
Ondansetron Blocks receptors that trigger the emetic reflex (5HT-3)
Erythromycin
Metoclopramide
May improve gastric emptying and intestinal motility
No clear benefit of one over the other
Limit use of metoclopramide due to risk of dystonic reaction and lower seizure threshold
G-tube venting and
equipment that allows
venting during feedings
Minimizes gastric distension and associated discomfort
Gastrojejunal tube
(GJ-tube)
Lessens gastric distension
G-tube venting possible while feeding through the J-tube
GI pain may not improve with J-tube feedings
Soy, partially
hydrolyzed, or
elemental formula
Management of protein hypersensitivity
Higher omolarity with elemental formula
Select antibiotics For Helicobacter pylori identified by stool antigen or endoscopy, or empirical trial for smallbowel bacterial overgrowth
Anti-reflux
surgery (fundoplication)
Consider empirical medication trials for problems outlined above before elective surgery
Some children will develop retching, bloating, and pain following fundoplication
G-tube: gastrostomy tube; GJ-tube: gastrojejunal tube; TCA: tricyclic antidepressant; VC: vomiting center.
5. Over-Feeding
Over-feeding was identified as the third most common contributor to feeding intolerance,
behind formula osmolarity and feeding rate [34]. Children with SNI have significantly lower energy
expenditure as assessed by indirect calorimetry [35,36]. Calorie estimates using guidelines for children
with cerebral palsy (CP) can over-estimate energy requirements in children with SNI by 30–40% [36–39].
Factors that contribute to this over-estimation include that children with SNI often have decreased
muscle mass, which can account for 20–30% of resting energy expenditure [35]. Other factors that
also decrease energy expenditure by approximately 25% include limited movement of extremities and
hypothermia [36,40].
Guidelines for energy requirements have been established for children with CP. Using length,
energy requirements are typically 12–15 kcal/cm for those who are ambulatory and 10–11 kcal/cm
for those who are non-ambulatory, with some needing only 6–9 kcal/cm or less as a result of those
factors that further lower energy expenditure [38,39]. Energy expenditure can also be determined
by estimating the physical activity coefficient factor to use with the resting energy expenditure (REE,
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in kcal/day). Many children with SNI require a factor of 0.8 (kcal/day = REE × 0.8), with some as low
as 0.5–0.6 [38]. This is in contrast to a factor of 1.5 to 1.6 for a typically developing, healthy child and a
factor of 1.1 for a child who is non-ambulatory due to CP.
The goal in children with feeding tubes who remain life-long dependent on others to estimate
calorie intake is to avoid excessive weight gain and to minimize associated symptoms of over-feeding,
including retching, emesis, and GI tract pain. Children at highest risk for over-estimating intake
include children with:
• Limited movement of extremities at baseline.
• A decrease in movement following improvement in symptoms (increase in baseline tone and
movement are common features associated with pain) [20].
• Hypothermia due to impaired central regulation of body temperature.
• Gradual decline in activity when there is a decline in function and health over months to years.
Fluid needs can also be overestimated in children with a low metabolic rate, given that energy
expenditure accounts for a portion of fluid needs. Of note, fluid requirement calculations based on
weight were developed in ambulatory individuals with higher metabolic rates. This recognition allows
a feed reduction trial without a need to maintain the same total fluid volume, when the goal of the
trial is to determine if this will reduce emesis and GI tract pain.
A discussion regarding a reduction in calories is best approached gently, given the symbolic
nature of feeding and nutrition. Language that may benefit families is an acknowledgment that it can
seem counter intuitive to suggest a reduction in feeds as potentially beneficial for a child. Taking time
to reflect on information can lessen associated fear and allow concerns to be adequately explored.
Some children will benefit from a feeding reduction trial when emesis, retching, or pain localized
to the GI tract persists, following a comprehensive assessment for testable/treatable sources and
management of common problems such as GERD and constipation. A 30% reduction of feeds is
suggested to ensure an adequate trial while monitoring for benefit. A dietician can determine the need
for micronutrient and protein supplementation when feeds are decreased. Along with monitoring
weight, parents can monitor for changes in how clothing is fitting. This author has observed children
with minimal to no change in weight when symptoms are improved following a reduction in feeds.
This may reflect improved retention of intake due to decreased emesis and decreased metabolic
expenditure due to a decrease in tone and movement when pain is reduced [20,38].
6. Empirical Trials
Many of the interventions listed in Table 2 require an empirical trial, including medications
directed at causes due to the altered nervous system given the lack of diagnostic tests. Information
regarding empirical trials directed at these problems, including dosing guidelines, is reviewed in detail
in this clinical report from the American Academy of Pediatrics [16].
6.1. Medication Trials
Recurrent emesis and GI tract pain can often be improved, though in some not completely
eliminated. The optimal plan can involve significant time and effort in those with recurrent symptoms
and is best guided by broader considerations [16]. Information to consider when starting an empirical
medication trial includes (1) response to previous medications; (2) interaction with other drugs;
(3) initial dose; (4) the need for titration to minimize adverse effects; (5) the minimal initial dose; and
(6) adverse effects [16]. Monitoring will determine whether there is adequate benefit and, if not, if a
second medication will be added while continuing the first medication. As an example, the use of
two or more medications with different mechanisms of action may reduce symptoms generated by
neuropathic pain and reduce adverse effects if synergistic benefit allows for dose reduction [16].
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6.2. Home Care Plans
Medications can modify symptoms generated by the altered nervous system, though breakthrough
symptoms can occur due to the inability to eliminate the cause. Parents can be empowered with care
plans to utilize for breakthrough symptoms. Interventions can be tried and then the care plan modified
as information is gained. As an example, some children will benefit from use of an as needed
suppository when retching or GI tract pain recurs, with such a trial determining if this is helpful
for a specific child. Such an intervention can lessen colonic distention if the intervention results in
a bowel movement, given the inability to know if there was incomplete evacuation with the last
bowel movement.
Information to consider and document in a care plan includes:
• Presenting symptoms (vomiting, retching, pain).
• Initial routine interventions (vent G-tube).
• Interventions for triggers due to GI tract distention (use as-needed suppository, use enema if no
results within 1-h of suppository, hold feeds for 2 h, hold feeds and give electrolyte replacement
overnight, reduce total feeds/fluids).
• Use of as-needed medications (options include as needed antacid, ondansetron, clonidine, or
benzodiazepine).
• When to call (call the clinic during the day or the on-call clinician after hours if symptoms persist
despite use of the interventions outlined).
As an example, this was a beneficial strategy for an 18-year-old with SNI, thought to be due to
birth anoxia, with recurrent episodes of abdominal distention and pain. Through trial and error, the
following care plan was developed. This allowed care during events to remain at home and lessened
repeat testing.
Initiate care plan for the following symptoms: persistent abdominal distention with discomfort
or vomiting.
• Vent G-tube, hold use × 2 h.
• If no stool that day, give fleet enema.
• Give pedialyte at 40 mL/h × 4 h, then 70 mL/h × 24–36 h.
• Give acetaminophen every 4–6 h × 3–4 doses.
• Use morphine as needed, as often as every 4 h.
• Update team.
7. Acute on Chronic Symptom Events
If the frequency or severity of events increases, there is a balance between two considerations:
assessment for a new acute source while considering a modification to a medication dose or an additional
empirical medication trial directed at the sources due to the altered nervous system. Past experience,
along with parental preference, will guide this balance. In a child with repeated negative tests, there
may be a shared decision to focus on modifying the chronic care plan, given the decreased likelihood of
the same tests identifying a new problem. A supportive and flexible approach can guide decisions in
the child with recurrent symptoms. Language at such times might include the following:
• “Most recent tests have been negative, and I have the option of increasing the dose of his
gabapentin or clonidine (I have the option to add a medication that targets the same symptoms in
a different way). It might make sense to adjust medications while considering tests. You know
your son best and I want you to feel comfortable with the plan. What makes best sense to you at
this time?”
• “I imagine this is hard as I talk about sources that can be improved but not fixed”.
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• “It must be hard as I talk about his nervous system being a reason for these symptoms when I don’t
have a test to tell you with certainty. What are your thoughts as we discuss this information?”
8. Intractable Feeding Intolerance and Features at End of Life
Persistent feeding intolerance following various interventions is an intensely stressful experience
for families of children with SNI. The assessment and management often reflect months of repeated
studies and various interventions. Though intractable feeding intolerance is not common, the inherent
challenges deserve consideration.
It can be beneficial, as further interventions outlined in Table 2 are considered, to simultaneously
be mindful that this may be part of an irreversible decline. Language at such times can include, “I hope
for as much benefit from this next trial, although I also want you to be prepared that we might not
have the hoped-for benefit. What is important to you as we consider these possibilities?” [41].
This can be challenging, as children with SNI often experience decline over a long period,
increasing the likelihood of testing and intervention trials of an irreversible problem. Alterations in GI
tract function that is under the control of the CNS [42,43] may be a result of ongoing neuronal apoptosis.
Changes in the CNS may account for why some children with SNI develop feeding intolerance that is
not amenable to medical interventions [44]. Other features that can suggest changes in CNS function
include altered alertness (pathways involved with arousal), altered regulation of body temperature
and heart rate (autonomic function), frequency of seizures, level of comfort (thalamus), and altered
vasomotor tone resulting in peripheral edema (hypothalamus and medulla), along with the regulation
of GI tract function (hypothalamus and medulla). The development of persistent peripheral edema
is the most likely to indicate irreversible changes, reported as a feature in the last weeks to months
of life in children with SNI, and as a terminal feature in adults with multiple sclerosis and CNS
tumors [45,46].
These considerations are important for parents to minimize over-testing at a time of diminishing
benefit. Palliative care teams can provide support and guidance throughout this process. Suggested
language includes: “These features can be due to changes in the brain. This means that the problems we
are seeing might not improve with available treatment. As we try the next intervention we discussed,
what is most important to you at this time?”, “I know that comfort is an important goal. I worry
that it has been difficult to meet this goal or that it will only be possible with increased sedation or a
decrease in total feeds. What are your thoughts?” [41]. Discussions may result in a shared decision to
redirect goals and change care plans, such as reconsidering the role of further testing, resuscitation,
and hospitalization.
The use of medical fluids and nutrition can be reviewed when there is persistent symptom
burden due to tube feedings that is not alleviated with available interventions. At such times the
use of a feeding tube can be viewed as a life-sustaining technology that may be prolonging suffering.
This allows one to consider the amount of benefit and harm when technology is becoming more
burdensome, even when that technology is “routine” to use. This is also a time to celebrate the years
of benefit that were provided by the feeding tube as development of harm from this intervention
is considered.
The process of considering peripheral nutrition as an alternative means of providing medical
nutrition and hydration in children with SNI can be considered in the context of how a child is doing
overall. Peripheral nutrition has greater likelihood of harm in the child with a variety of features that
might be due to alterations in the CNS. A family may view such technology as burdensome and as
prolonging suffering, when a child has experienced a decline in other areas of health and function. It is
also helpful to consider what goal is intended by the intervention. Examples of goals are to improve
comfort, to restore health, or to maintain life.
Discontinuing medical nutrition and hydration remains challenging and controversial, because
of the symbolic significance of nutrition, the myths about dehydration and “starvation,” and the
under-recognition of symptoms that can be due to medical nutrition and hydration. It is ethically
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permissible to discontinue medical nutrition and hydration that is contributing to suffering and
prolonging the dying process [47]. Parents interviewed about their decision to forgo artificial nutrition
and hydration (FANH) did not regret their decision [48]. This represented the paradoxical experience
of not wanting their child to die yet concluding that FANH was the best of all options available, even
viewed “as the only thing that made any sense”. The decision to FANH included that all children
were viewed to have a significant alteration in quality of life due to pain and suffering and a decline in
health that was not viewed as likely to improve. Family members also wrote about their experience
regarding the harm they perceived when medical nutrition and hydration was used for their child
with a neurodegenerative condition [49]. At such times, an approach of feeding to an amount that
allows comfort can be beneficial and allow time to reflect on information while ensuring the child’s
comfort. This topic is reviewed in greater detail elsewhere [47,48,50].
9. Conclusions
Vomiting, GI tract pain, and feeding intolerance are common problems in children with SNI.
Awareness of sources with tests, sources due to the altered nervous system and risk for over-estimating
calorie needs can then guide management strategies and lessen symptom burden in many. Some will
progress to intractable feeding intolerance, likely due to further alterations in the CNS. Using the
information in this review can improve comfort throughout life and lessen suffering at the end of life
for children with SNI.
Conflicts of Interest: The author declares no conflict of interest.
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